Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Danne

Showing results (21-30 of 186) with videos related to

Pageof 19
Sort By:
Clinical Pharmacokinetics|February 17, 2017
A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 DiabetesTim Heise, Thomas R Pieber, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 2, 2024
Safety and Effectiveness of Glargine 300 U/ml After Switching from Basal Insulins in Patients with Type 1 Diabetes: COMET-T StudyStefan Gölz, Julia K Mader, Stefan Bilz, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|February 2, 2002
Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adultsOlga Kordonouri, Reinhard Hartmann, Anette Grüters-Kieslich, et al.
Diabetes Technology & Therapeutics|February 5, 2011
Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetesAreti Philotheou, Silva Arslanian, László Blatniczky, et al.
Pediatric Diabetes|June 7, 2007
Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetesDorothee Deiss, Olga Kordonouri, Reinhard Hartmann, et al.
Diabetes Care|October 28, 2003
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetesThomas Danne, Kerstin Lüpke, Kerstin Walte, et al.
Diabetes Research and Clinical Practice|June 21, 2016
Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategyPeter Bramlage, Tobias Bluhmki, Wolfgang Rathmann, et al.
Pediatric Diabetes|February 7, 2017
Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitusMaryam Fath, Thomas Danne, Torben Biester, et al.
Pediatric Diabetes|July 7, 2012
Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapyOlga Kordonouri, Reinhard Hartmann, Kerstin Remus, et al.
Journal of Diabetes Science and Technology|November 10, 2025
Optimizing Type 1 Diabetes Screening in People With Family History: A German PerspectiveThomas Danne, Thomas M Kapellen, Sebastian A Widholz, et al.
Pageof 19

Showing results (21-30 of 186) with videos related to

Sort By:
Pageof 19
Clinical Pharmacokinetics|February 17, 2017
A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 DiabetesTim Heise, Thomas R Pieber, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 2, 2024
Safety and Effectiveness of Glargine 300 U/ml After Switching from Basal Insulins in Patients with Type 1 Diabetes: COMET-T StudyStefan Gölz, Julia K Mader, Stefan Bilz, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|February 2, 2002
Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adultsOlga Kordonouri, Reinhard Hartmann, Anette Grüters-Kieslich, et al.
Diabetes Technology & Therapeutics|February 5, 2011
Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetesAreti Philotheou, Silva Arslanian, László Blatniczky, et al.
Pediatric Diabetes|June 7, 2007
Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetesDorothee Deiss, Olga Kordonouri, Reinhard Hartmann, et al.
Diabetes Care|October 28, 2003
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetesThomas Danne, Kerstin Lüpke, Kerstin Walte, et al.
Diabetes Research and Clinical Practice|June 21, 2016
Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategyPeter Bramlage, Tobias Bluhmki, Wolfgang Rathmann, et al.
Pediatric Diabetes|February 7, 2017
Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitusMaryam Fath, Thomas Danne, Torben Biester, et al.
Pediatric Diabetes|July 7, 2012
Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapyOlga Kordonouri, Reinhard Hartmann, Kerstin Remus, et al.
Journal of Diabetes Science and Technology|November 10, 2025
Optimizing Type 1 Diabetes Screening in People With Family History: A German PerspectiveThomas Danne, Thomas M Kapellen, Sebastian A Widholz, et al.
Pageof 19